Pharmaceutical Executive: September 2026

View the Pharmaceutical Executive September 2026 issue in an interactive format.

Survey data captured in our September issue puts a spotlight on the mounting pressures facing CEOs of emerging biotech companies — and why trusted counsel matters more than ever to leaders in this group.

Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.

A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

As leaders, we must evaluate solutions to fragmentation by asking the right questions.

Why clinical out-of-home marketing has finally become responsive after decades of running static, scheduled messages.

A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset.

Unmet need is likely a new battlefield impacting prior authorization.